Answers are grounded in this paper and cite their sources.
In Brief For patients with type 2 diabetes who require add-on therapy to metformin plus basal insulin, GLP-1 receptor agonists may be a favorable option because they effectively manage postprandial glucose, reduce body weight, and have an overall favorable safety profile compared to other agents. Given the wide range of treatment combinations available for type 2 diabetes management, health professionals must partner with patients to determine the best choices based on patients' individual lifestyle, resources, and treatment goals.
No takes yet. Share an insight, caveat, or question.
Debbie Hinnen (2015) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: